Isavuconazole: A comprehensive review of spectrum of activity of a new triazole

George Richard Thompson, Nathan P. Wiederhold

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Isavuconazole is a new triazole currently undergoing phase III clinical trials. This compound has shown in vitro activity against a large number of clinically important yeasts and moulds including Aspergillus spp., Fusarium spp., Scedosporium spp., Candida spp., the Zygomycetes and Cryptococcus spp. Similar to voriconazole, reduced in vitro activity is seen against Histoplasma capsulatum. In vivo efficacy has been demonstrated in murine models of invasive aspergillosis and candidiasis. Additionally, there are several potential pharmacokinetic and drug-drug interaction advantages of this compound over existing antifungal agents. This review summarizes existing data that has been either published or presented at international symposia.

Original languageEnglish (US)
Pages (from-to)291-313
Number of pages23
JournalMycopathologia
Volume170
Issue number5
DOIs
StatePublished - Nov 2010

Fingerprint

Scedosporium
Histoplasma capsulatum
drug interactions
triazoles
Triazoles
candidiasis
aspergillosis
Candida
Aspergillus
molds (fungi)
Fusarium
pharmacokinetics
fungicides
clinical trials
animal models
Invasive Candidiasis
yeasts
Histoplasma
Cryptococcus
drugs

Keywords

  • Antifungal
  • Fungicidal
  • Fungistatic
  • In vitro activity
  • In vivo studies
  • Isavuconazole

ASJC Scopus subject areas

  • Plant Science
  • Agronomy and Crop Science
  • Applied Microbiology and Biotechnology
  • Microbiology
  • veterinary (miscalleneous)

Cite this

Isavuconazole : A comprehensive review of spectrum of activity of a new triazole. / Thompson, George Richard; Wiederhold, Nathan P.

In: Mycopathologia, Vol. 170, No. 5, 11.2010, p. 291-313.

Research output: Contribution to journalArticle

@article{d2677d95d4464429a49c9d1210c5a4a7,
title = "Isavuconazole: A comprehensive review of spectrum of activity of a new triazole",
abstract = "Isavuconazole is a new triazole currently undergoing phase III clinical trials. This compound has shown in vitro activity against a large number of clinically important yeasts and moulds including Aspergillus spp., Fusarium spp., Scedosporium spp., Candida spp., the Zygomycetes and Cryptococcus spp. Similar to voriconazole, reduced in vitro activity is seen against Histoplasma capsulatum. In vivo efficacy has been demonstrated in murine models of invasive aspergillosis and candidiasis. Additionally, there are several potential pharmacokinetic and drug-drug interaction advantages of this compound over existing antifungal agents. This review summarizes existing data that has been either published or presented at international symposia.",
keywords = "Antifungal, Fungicidal, Fungistatic, In vitro activity, In vivo studies, Isavuconazole",
author = "Thompson, {George Richard} and Wiederhold, {Nathan P.}",
year = "2010",
month = "11",
doi = "10.1007/s11046-010-9324-3",
language = "English (US)",
volume = "170",
pages = "291--313",
journal = "Mycopathologia",
issn = "0301-486X",
publisher = "Springer Netherlands",
number = "5",

}

TY - JOUR

T1 - Isavuconazole

T2 - A comprehensive review of spectrum of activity of a new triazole

AU - Thompson, George Richard

AU - Wiederhold, Nathan P.

PY - 2010/11

Y1 - 2010/11

N2 - Isavuconazole is a new triazole currently undergoing phase III clinical trials. This compound has shown in vitro activity against a large number of clinically important yeasts and moulds including Aspergillus spp., Fusarium spp., Scedosporium spp., Candida spp., the Zygomycetes and Cryptococcus spp. Similar to voriconazole, reduced in vitro activity is seen against Histoplasma capsulatum. In vivo efficacy has been demonstrated in murine models of invasive aspergillosis and candidiasis. Additionally, there are several potential pharmacokinetic and drug-drug interaction advantages of this compound over existing antifungal agents. This review summarizes existing data that has been either published or presented at international symposia.

AB - Isavuconazole is a new triazole currently undergoing phase III clinical trials. This compound has shown in vitro activity against a large number of clinically important yeasts and moulds including Aspergillus spp., Fusarium spp., Scedosporium spp., Candida spp., the Zygomycetes and Cryptococcus spp. Similar to voriconazole, reduced in vitro activity is seen against Histoplasma capsulatum. In vivo efficacy has been demonstrated in murine models of invasive aspergillosis and candidiasis. Additionally, there are several potential pharmacokinetic and drug-drug interaction advantages of this compound over existing antifungal agents. This review summarizes existing data that has been either published or presented at international symposia.

KW - Antifungal

KW - Fungicidal

KW - Fungistatic

KW - In vitro activity

KW - In vivo studies

KW - Isavuconazole

UR - http://www.scopus.com/inward/record.url?scp=78049352249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049352249&partnerID=8YFLogxK

U2 - 10.1007/s11046-010-9324-3

DO - 10.1007/s11046-010-9324-3

M3 - Article

C2 - 20524153

AN - SCOPUS:78049352249

VL - 170

SP - 291

EP - 313

JO - Mycopathologia

JF - Mycopathologia

SN - 0301-486X

IS - 5

ER -